YOKNEAM, Israel, July 25, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to announce the completion of a significant intellectual property (IP) transaction in the women's health and wellness market.
InMode has acquired all the intellectual property assets of Viveve Medical Inc. Viveve is a medical technology company focused on women's wellness and the treatment of female stress urinary incontinence (SUI). All of Viveve's worldwide patents will be transferred and registered under InMode Ltd.
The acquisition of Viveve's patent portfolio, in addition to an exclusive licensing agreement previously signed with the University of California relating to a bladder denervation patent, coupled with InMode's existing robust patent portfolio, fortifies InMode as the global market leader in women's wellness products development.
"Development of products for Women's Wellness continues to be a strategic pillar of our long-term growth strategy. By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercializing innovative technologies. InMode protects its IP worldwide against any company that attempts to infringe its proprietary rights," said Moshe Mizrahy, InMode CEO.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Press Contact:
Behrman Communications
Amanda Reinstein
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
MS-IR LLC
Miri Segal – Scharia
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 917-607-8654
| Last Trade: | US$17.88 |
| Daily Change: | -0.03 -0.17 |
| Daily Volume: | 633,939 |
| Market Cap: | US$1.360B |
September 04, 2024 August 06, 2024 July 31, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
